Positive News SentimentPositive NewsNASDAQ:ANNX Annexon (ANNX) Stock Forecast, Price & News $2.81 -0.07 (-2.43%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$2.79▼$3.0650-Day Range$2.10▼$6.3752-Week Range$2.07▼$7.65Volume567,169 shsAverage Volume696,973 shsMarket Capitalization$149.17 millionP/E RatioN/ADividend YieldN/APrice Target$14.71 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Annexon MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside423.6% Upside$14.71 Price TargetShort InterestHealthy5.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.70Based on 2 Articles This WeekInsider TradingAcquiring Shares$639,000 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.18) to ($1.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 starsMedical Sector197th out of 987 stocksPharmaceutical Preparations Industry87th out of 466 stocks 3.4 Analyst's Opinion Consensus RatingAnnexon has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.71, Annexon has a forecasted upside of 423.6% from its current price of $2.81.Amount of Analyst CoverageAnnexon has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.72% of the float of Annexon has been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 4.2.Change versus previous monthShort interest in Annexon has recently decreased by 13.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAnnexon does not currently pay a dividend.Dividend GrowthAnnexon does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANNX. Previous Next 3.2 News and Social Media Coverage News SentimentAnnexon has a news sentiment score of 1.70. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Annexon this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for ANNX on MarketBeat in the last 30 days. This is a decrease of -36% compared to the previous 30 days.MarketBeat Follows2 people have added Annexon to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Annexon insiders have bought more of their company's stock than they have sold. Specifically, they have bought $639,000.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.11% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Annexon are expected to grow in the coming year, from ($2.18) to ($1.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annexon is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annexon is -1.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnexon has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Annexon (NASDAQ:ANNX) StockAnnexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.Read More Receive ANNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter. Email Address ANNX Stock News HeadlinesJune 1, 2023 | americanbankingnews.comBain Capital Life Sciences Inv Buys 300,000 Shares of Annexon, Inc. (NASDAQ:ANNX) StockMay 29, 2023 | americanbankingnews.comAnnexon, Inc. (NASDAQ:ANNX) Sees Significant Decrease in Short InterestJune 10, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 28, 2023 | americanbankingnews.comAnnexon (NASDAQ:ANNX) Cut to "Neutral" at JPMorgan Chase & Co.May 27, 2023 | americanbankingnews.comAnnexon (NASDAQ:ANNX) Downgraded to "Neutral" at Bank of AmericaMay 27, 2023 | americanbankingnews.comAnnexon (NASDAQ:ANNX) Price Target Cut to $7.00 by Analysts at BTIG ResearchMay 27, 2023 | americanbankingnews.comTraders Buy High Volume of Put Options on Annexon (NASDAQ:ANNX)May 26, 2023 | msn.comB of A Securities Downgrades Annexon (ANNX)June 10, 2023 | Vector Vest (Ad)Free Stock Analysis Report: Get Buy, Sell, or Hold RecommendationGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. May 26, 2023 | americanbankingnews.comAnnexon (NASDAQ:ANNX) Downgraded to Neutral at JPMorgan Chase & Co.May 25, 2023 | seekingalpha.comACCD, GSIT and ANNX are among after hour moversMay 25, 2023 | markets.businessinsider.comAnalyst Expectations for Annexon's FutureMay 25, 2023 | msn.comWhy Annexon (ANNX) Stock Is Getting HammeredMay 25, 2023 | msn.comBTIG Maintains Annexon (ANNX) Buy RecommendationMay 25, 2023 | finance.yahoo.comAnnexon's Eye Disease Drug Reports Mixed Trial Results, Will Focus On Planned Late-Stage StudyMay 25, 2023 | finance.yahoo.comWhy Shares of Annexon Are Plummeting ThursdayMay 25, 2023 | americanbankingnews.comAnnexon, Inc. (NASDAQ:ANNX) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 25, 2023 | markets.businessinsider.comBTIG Reaffirms Their Buy Rating on Annexon Biosciences (ANNX)May 25, 2023 | msn.comAnnexon Drops after Geographic Atrophy Candidate DisappointsMay 25, 2023 | seekingalpha.comAnnexon geographic atrophy candidate fails in phase 2; down 20%May 17, 2023 | americanbankingnews.comAnalysts Issue Forecasts for Annexon, Inc.'s FY2023 Earnings (NASDAQ:ANNX)May 17, 2023 | americanbankingnews.comAnnexon's (ANNX) Overweight Rating Reiterated at Cantor FitzgeraldMay 10, 2023 | americanbankingnews.comAnnexon (NASDAQ:ANNX) Releases Earnings Results, Hits EstimatesMay 9, 2023 | finanznachrichten.deAnnexon Biosciences: Annexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline ProgressMay 9, 2023 | marketwatch.comAnnexon Reports First Quarter 2023 Financial Results and Highlights Recent Pipeline ProgressMay 9, 2023 | markets.businessinsider.comAnalyst Ratings for AnnexonMay 9, 2023 | markets.businessinsider.comAnnexon Biosciences (ANNX) Gets a Buy from H.C. WainwrightSee More Headlines ANNX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANNX Company Calendar Last Earnings5/08/2023Today6/09/2023Next Earnings (Estimated)8/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ANNX CUSIPN/A CIK1528115 Webwww.annexonbio.com Phone650-822-5500Fax650-636-9773Employees61Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.71 High Stock Price Forecast$30.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+423.6%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($2.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-141,950,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-66.42% Return on Assets-53.44% Debt Debt-to-Equity RatioN/A Current Ratio10.14 Quick Ratio10.14 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.85 per share Price / Book0.58Miscellaneous Outstanding Shares53,084,000Free Float42,940,000Market Cap$149.17 million OptionableNot Optionable Beta0.50 Key ExecutivesMr. Douglas Love J.D. (Age 54)Esq., CEO, Pres & Director Comp: $830.99kDr. Larry C. Mattheakis Ph.D. (Age 65)Exec. VP & Chief Scientific Officer Comp: $296.45kDr. Ted Yednock Ph.D. (Age 64)Exec. VP, Chief Innovation Officer & Chairman of the Scientific Advisory Board Comp: $614.6kDr. Arnon Rosenthal Ph.D. (Age 66)Founder Ms. Jennifer Lew (Age 49)Exec. VP & CFO Miriam MasonSr. VP of Corp. CommunicationsMr. Michael Overdorf M.B.A. (Age 52)Exec. VP & Chief Bus. Officer Henk-Andre Kroon M.D.Sr. VP of Translational MedicineMirella Villa Del ToroSec.More ExecutivesKey CompetitorsXBiotechNASDAQ:XBITLarimar TherapeuticsNASDAQ:LRMRPuma BiotechnologyNASDAQ:PBYIMerrimack PharmaceuticalsNASDAQ:MACKCue BiopharmaNASDAQ:CUEView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 12,166 shares on 6/1/2023Ownership: 0.023%Bain Capital Life Sciences InvBought 300,000 shares on 5/25/2023Total: $639,000.00 ($2.13/share)Geode Capital Management LLCBought 15,016 shares on 5/16/2023Ownership: 0.729%Jane Street Group LLCBought 136,859 shares on 5/16/2023Ownership: 0.302%State Street CorpBought 32,300 shares on 5/16/2023Ownership: 0.293%View All Insider TransactionsView All Institutional Transactions ANNX Stock - Frequently Asked Questions Should I buy or sell Annexon stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Annexon in the last year. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ANNX shares. View ANNX analyst ratings or view top-rated stocks. What is Annexon's stock price forecast for 2023? 7 Wall Street research analysts have issued 12-month price objectives for Annexon's stock. Their ANNX share price forecasts range from $3.00 to $30.00. On average, they predict the company's share price to reach $14.71 in the next twelve months. This suggests a possible upside of 423.6% from the stock's current price. View analysts price targets for ANNX or view top-rated stocks among Wall Street analysts. How have ANNX shares performed in 2023? Annexon's stock was trading at $5.17 at the start of the year. Since then, ANNX shares have decreased by 45.6% and is now trading at $2.81. View the best growth stocks for 2023 here. When is Annexon's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023. View our ANNX earnings forecast. How were Annexon's earnings last quarter? Annexon, Inc. (NASDAQ:ANNX) announced its quarterly earnings data on Monday, May, 8th. The company reported ($0.52) EPS for the quarter, hitting analysts' consensus estimates of ($0.52). What ETFs hold Annexon's stock? ETFs with the largest weight of Annexon (NASDAQ:ANNX) stock in their portfolio include Simplify Propel Opportunities ETF (SURI).iShares Neuroscience and Healthcare ETF (IBRN). What other stocks do shareholders of Annexon own? Based on aggregate information from My MarketBeat watchlists, some companies that other Annexon investors own include Alibaba Group (BABA), CVS Health (CVS), Home Depot (HD), Procter & Gamble (PG), Johnson & Johnson (JNJ), Raytheon Technologies (RTX), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO) and Pfizer (PFE). When did Annexon IPO? (ANNX) raised $150 million in an IPO on Friday, July 24th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen acted as the underwriters for the IPO. What is Annexon's stock symbol? Annexon trades on the NASDAQ under the ticker symbol "ANNX." Who are Annexon's major shareholders? Annexon's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alerce Investment Management L.P. (13.29%), GMT Capital Corp (2.65%), Acadian Asset Management LLC (1.52%), Simplify Asset Management Inc. (1.23%), Geode Capital Management LLC (0.73%) and Renaissance Technologies LLC (0.67%). Insiders that own company stock include Bain Capital Life Sciences Fun, Bain Capital Life Sciences Inv, Douglas Love, James E Flynn, Jennifer Lew, Michael Overdorf, Muneer A Satter, Sanjay Keswani and Ted Yednock. View institutional ownership trends. How do I buy shares of Annexon? Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Annexon's stock price today? One share of ANNX stock can currently be purchased for approximately $2.81. How much money does Annexon make? Annexon (NASDAQ:ANNX) has a market capitalization of $149.17 million. The company earns $-141,950,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. How can I contact Annexon? The official website for the company is www.annexonbio.com. The company can be reached via phone at 650-822-5500, via email at swheeler@wheelhouselsa.com, or via fax at 650-636-9773. This page (NASDAQ:ANNX) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.